Atai Life Sciences Valued At More Than $3 Billion After IPO
Image courtesy | Nasdaq

Ringing the Nasdaq Opening Bell on Friday was Berlin-based psychedelic biopharmaceutical company Atai Life Sciences. It began trading Friday under the ticker symbol “ATAI”. The company’s 15 million shares opened at $15 and peaked at $22 before dropping to $16.50 at the close of trading Friday. Atai’s co-founder and CEO Florian Brand rang the Opening Bell alongside Founder and Chairman Christian Angermayer, and Srinivas Rao, Co-Founder and CSO.

Atai has raised more than $360 million since it launched in 2018, with funding from PayPal founder Peter Thiel. It raised more than $225 million on its first day of trading. It’s now valued at more than $3 billion.

One of a growing roster of psychedelic lifestyle brands to go public, Atai’s Nasdaq listing joins MindMed (MNMD) and Compass Pathways (CMPS), among others. (Read more: 21 publicly traded psychedelic companies.)

Included in Atai’s portfolio are a dozen companies working with psychedelic substances such as ketamine, MDMA, ibogaine, and DMT for mental health treatments. One of its drugs that contain psilocybin, the psychedelic component in a number of mushrooms, was found to be as effective as the widely used antidepressant drug escitalopram, marketed as Cipralex and Lexapro.

According to Angermayer, Atai’s work with psychedelics aims to treat psychiatric problems created by modern life. “The world we are building is a bad place for our brains,” he said.

Image courtesy of Nasdaq

Jill Ettinger is the co-founder and global editorial director for sustainable luxury and wellness platform, Ethos.

Similar Posts

My NEW Top 5 Psychedelic Stocks for 2021 || MindMed, NUMI, Atai and More

My NEW Top 5 Psychedelic Stocks for 2021 || MindMed, NUMI, Atai and More

Listen, Videos

Here are our Top 5 Best Psychedelic Stock Picks for 2021. For those who have watched our top 5 shroom stocks for 2020, you might notice that some stocks have stayed and others have been replaced because they have proven to be worthy of The Psychedelic Investor’s list by filling in the top 3 factors that we look at before investing in the psychedelic medicines industry, such as:
Clinical Trial Progress
Molecules & Compounds Pipeline
The Company’s war chest to sustain growth as a biotech company in a new industry

But why invest in psychedelic stocks?
Ever since last year, celebrity investors such as Kevin O’Leary and Peter Thiel decided to invest in the psychedelic/ shroom stocks industry, the industry grew from 2 or 3 companies to approximately 30 in 2021. This is probably one of the main reasons why we call this phenomenon the SHROOM BOOM!
But why do such investors seem to believe so much in the potential explosive growth of psychedelic stocks?
1. Psychedelics have been shown in many recent clinical trials to help a variety of mental health issues, from addiction, to depression to PTSD and more.
2.These psychedelic companies are attempting to disrupt the 100 billion annual industry for mental health pharmaceuticals.
3.These psychedelic compounds have the potential to help millions world wide, this also presents an amazing opportunity for early investors.
4.Smart investors might realize that rather than going all in on one company in the field, it is probably best to diversify your risk and create a Psychedelic Medicines portfolio.

So our top 5 Shroom Stock Pics for 2021 are:
5. Cybin ( CYBN on NEO & CLXPF on the OTC)
4. Numinus Wellness (LKYSF on the OTC & NUMI on the TSX)
3. Compass Pathways (CMPS on Nasdaq)
2. Atai Life Sciences – Soon to IPO on the Nasdaq
1 Mind Medicine or MindMed (MMED on NEO MNMD on Nasdaq & MMQ on FRA)
Link to Cybin (CYBN) : https://www.cybin.com/
Link to Numinus (NUMI) : https://numinus.ca/
Link to Compass Pathways (CMPS) : https://ir.compasspathways.com/static-files/fe6cc477-a2ee-4b4a-bd46-8f8df0b62f30
Link To Atai life Sciences: https://www.atai.life/
Linke To MindMed (MMED / MNMD / MMQ) https://mindmed.co/

Timestamps:
0:00 – Intro
1:58 – Ranking criteria
3:42 – Cybin (CYBN) ( CLXPF)
6:24 – Numinus Wellness ( NUMI)
10:04 – Compass Pathways (CMPS)
13:52 – Atai Life Sciences
18:50 – MindMed ( MMED / MNMD/ MMQ )

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

Clinical trials :

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #CMPSStock